The HER2/PI3K/Akt signaling pathway is one of the multidrug-related pathways, and it is involved in breast cancer chemoresistance against a panel of anticancer drugs such as the anthracyclines adriamycin, epirubicin and mitoxantrone [133]. Here, AKT1 is linked to breast carcinoma.